[EN] AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR COUPLÉ À LA PROTÉINE G DE TYPE AZÉDITINYLE
申请人:PROSIDION LTD
公开号:WO2009050523A1
公开(公告)日:2009-04-23
Compounds of formula (I) or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.
Compounds of formula (I): or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.
TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING GRANISETRON
申请人:Choi Hoo-Kyun
公开号:US20100285133A1
公开(公告)日:2010-11-11
Disclosed herein is a transdermal system in a matrix form capable of enhancing granisetron carrying efficiency and improving transdermal absorption while inhibiting recrystallization, which comprises: at least one transdermal enhancer selected from a group consisting of polyglyceryl-3 oleate, polyethyleneglycol-20 almond glyceride, polyethyleneglycol-12 palm kernel glyceride, isopropyl myristate and oleyl alcohol; and an acrylate polymer.
US9066886B2
申请人:——
公开号:US9066886B2
公开(公告)日:2015-06-30
[EN] TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING GRANISETRON<br/>[FR] SYSTÈME D'ADMINISTRATION TRANSDERMIQUE DE MÉDICAMENT CONTENANT DU GRANISÉTRON
申请人:ECHO PACIFIC LTD
公开号:WO2009088142A1
公开(公告)日:2009-07-16
Disclosed herein is a transdermal system in a matrix form capable of enhancing granisetron carrying efficiency and improving transdermal absorption while inhibiting recrystallization, which comprises: at least one transdermal enhancer selected from a group consisting of polyglyceryl-3 oleate, polyethyleneglycol-20 almond glyceride, polyethyleneglycol-12 palm kernel glyceride, isopropyl myristate and oleyl alcohol; and an acrylate polymer.